Sensydia raises $6M to bring catheter-free heart testing to the clinic
What's the deal? Sensydia, a Los Angeles clinical-stage medical technology company, has closed an oversubscribed early-stage round of more than $6 million. Colle Capital PartnersDealroom has a profile for this one. Try Dealroom → led the financing, with support from Orlando Health VenturesDealroom has a profile for this one. Try Dealroom →.
What's the endgame? The money will fund Sensydia's ACOUSTIC-1 study for its Cardiac Performance System (CPS) through FDA authorisation and support preparation for commercial launch. CPS assesses cardiac function by capturing acoustic and electrical signals and analysing them with AI, giving clinicians pulmonary pressure readings without invasive catheterisation.
Why now? In July 2026, a new Category III CPT code, 1036T, took effect for non-invasive hemodynamic assessment. It covers the same three-element approach — passive signal acquisition, algorithmic analysis, and physician interpretation — on which CPS is built.
The device targets heart failure and pulmonary hypertension, conditions where clinicians currently rely on invasive procedures to measure pressure. CPS has received FDA Breakthrough Device designation.
What they're saying: "We built CPS to give clinicians objective pressure information in the office, where therapy decisions are made," said Anthony Arnold, chief executive officer of Sensydia.
Victoria Grace, founding partner of Colle Capital Partners, pointed to the reimbursement groundwork. "That discipline, together with a CPT code already in place, gives us real confidence in this team," she said.
The signal: At $6 million, this is a modest early-stage round, but the timing around a newly live billing code shows how reimbursement pathways can shape when medtech companies raise and commercialise. For Sensydia, the backing of a hospital-system investor in Orlando Health Ventures offers a potential route to clinical adoption.
Read more: pr.sandyjournal.com
Image credit: Sensydia Corporation
